EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics of casticin 3’-glucuronide in a phase I trial in healthy volunteers after administration of different dosages of Vitex agnus-castus BNO 1095

A Neumann, D Fitz, M Soeberdt, C Abels

Planta Medica · 01.03.2026 · 92 (03) · 391

DOI: 10.1055/s-0045-1815382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von A Neumann und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitex agnus-castus L., fructus has a long history of medicinal use in the treatment of gynaecological disorders like premenstrual syndrome, irregular menstruation and mastodynia [ 1 ]. However, pharmacokinetics of VAC constituents in humans have not been studied so far; even in animals only scarce data is available. A high-resolution LC-ToF-MS bioavailability screening in rat plasma identified casticin-3’-glucuronide as one of the most intense signals detected after oral administration of VAC dry extract. This phase II metabolite of the flavone casticin – itself representing a major constituent of VAC [ 2 ] – was therefore selected as marker substance to study the pharmacokinetics of VAC in a single center, open-label phase I clinical trial (EudraCT number 2022-003480-20). Healthy volunteers (n=36; average age 31.4 years, 24 female/12 male) received 8 single oral doses of 80, 40 or 20 mg VAC BNO 1095 on 8 consecutive days. Plasma concentrations of casticin-3’-glucuronide were quantified by HPLC-MS/MS following protein precipitation and further sample clean-up using Ostro TM plates (Waters). The quantitation method was fully validated according to the ICH M10 guideline and provided accurate and precise results down to an LLOQ of 0.1 ng/ml. AUC values of casticin-3’-glucuronide were found to be dose proportional and likewise, Cmax concentrations increased with ascending dosages. Accumulating effects were observed after multiple dosing on day 8. This is the first study reporting bioavailability and pharmacokinetic data for VAC in humans. Furthermore, safety and tolerability were confirmed for VAC dosages even 4x higher compared to the marketed product Agnucaston ®​ 20 mg. Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Neumann, A., Fitz, D., Soeberdt, M., & Abels, C. (2026). Pharmacokinetics of casticin 3’-glucuronide in a phase I trial in healthy volunteers after administration of different dosages of Vitex agnus-castus BNO 1095. Planta Medica, 92(03), 391. https://doi.org/10.1055/s-0045-1815382

Vancouver

Neumann A, Fitz D, Soeberdt M, Abels C. Pharmacokinetics of casticin 3’-glucuronide in a phase I trial in healthy volunteers after administration of different dosages of Vitex agnus-castus BNO 1095. Planta Medica. 2026;92(03):391. doi:10.1055/s-0045-1815382

BibTeX
@article{Neumann2026,
  author = {Neumann, A and Fitz, D and Soeberdt, M and Abels, C},
  title = {Pharmacokinetics of casticin 3’-glucuronide in a phase I trial in healthy volunteers after administration of different dosages of Vitex agnus-castus BNO 1095},
  journal = {Planta Medica},
  year = {2026},
  volume = {92},
  number = {03},
  pages = {391},
  doi = {10.1055/s-0045-1815382}
}
Kostenlos starten →